Latest News - NightstaRx

Friday, September 01, 2017 | Earnings & Financials, Retina, NightstaRx

Nightstar Files Registration Statement For Proposed Initial Public Offering

Nightstar Therapeutics a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, announced that it has filed a registration statement on Form F-1 with the U.S. S…

Read the full story

Thursday, April 28, 2016 | Clinical Trials, NightstaRx

NightstaRx Reports Long-Term Benefits of Gene Therapy for Inherited Form of Progressive Blindness

NightstaRx announced the publication from the University of Oxford of promising clinical results and long-term benefits of choroideremia gene therapy in this week’s issue of the New England Jour…

Read the full story

Thursday, November 12, 2015 | Clinical Trials, NightstaRx

NightstaRx Announces the Start of a Miami Gene Therapy Study to Treat Choroideremia

NightstaRx announced that the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has begun enrolling and dosing subjects in a phase 2 clinical trial to treat choroideremi…

Read the full story

Monday, November 09, 2015 | Earnings & Financials, NightstaRx

NightstaRx Closes $35 Million Series B Funding to Advance Inherited Retinal Disease Pipeline

NightstaRx, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announced a $35 million Series B financing round, according to a company news relea…

Read the full story

Monday, June 29, 2015 | Partnerships, NightstaRx

NightstaRx and The University of Alberta Announce the Start of the First Canadian Gene Therapy Study to Treat Choroideremia

NightstaRx announced that the University of Alberta has begun enrolling and dosing subjects in a phase 2 clinical trial of the company’s gene therapy for the treatment of choroideremia (CHM), ac…

Read the full story